We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Archemix Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Nuvelo
News

Archemix Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Nuvelo

Archemix Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Nuvelo
News

Archemix Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Nuvelo

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Archemix Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Nuvelo"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Archemix Corp. has announced that it will receive a $1 million milestone payment from its collaborator Nuvelo, Inc. The milestone payment has been triggered by Nuvelo’s enrollment of the first volunteer in a Phase 1 study of NU172, a thrombin-inhibiting aptamer.

The Phase 1 study is being conducted at a single center with approximately 30 healthy male volunteers and is designed to determine the safety, tolerability and pharmacokinetics of escalating doses of NU172.

NU172 is an aptamer designed to directly inhibit thrombin's ability to stimulate blood clot formation in the setting of medical procedures where human blood is exposed to foreign materials. Specifically, NU172 is being studied for use as a potential short-acting anticoagulant during procedures such as coronary artery bypass graft surgery and percutaneous interventions.

“We are pleased that Nuvelo has advanced NU172 into clinical trials,” commented Dr. Errol De Souza, President and Chief Executive Officer of Archemix. “NU172 demonstrates the productivity of our aptamer discovery efforts and we look forward to its clinical development.”

Nuvelo is solely responsible for further development and commercialization of NU172. However, Archemix is eligible to receive additional milestone payments if the program advances further in clinical trials and will also receive royalties on any sales of NU172.

Archemix also retains the option to share in a specified percentage of the profits from any sales of NU172 in exchange for paying an equal percentage of its development and commercialization costs and in lieu of being eligible to receive milestone payments and royalties with respect to NU172.

Advertisement